Board of Directors member

Dr. Rod MacKenzie is Executive Vice President, Chief Development Officer for Pfizer. Rod is responsible for the development and advancement of Pfizer’s pipeline of medicines in several therapeutic areas, including cardiovascular and metabolic disease, inflammation and immunology, neuroscience and pain, oncology and rare disease. He serves on the corporate Portfolio Strategy and Investment Committee and is a member of Pfizer’s Executive Leadership Team.

Rod began his career at Pfizer as a Research Scientist and worked in many medicinal chemistry programmes across various therapeutic areas. Rod is the co-inventor of darifenacin Enablex (TM). He has held numerous leadership positions at Pfizer, including Head of PharmaTherapeutics Research and Development; Senior Vice President, Head of Worldwide Research; and Senior Vice President, Head of Drug Safety R&D and Comparative Medicine.

Rod graduated from the University of Glasgow with a 1st Class Honors degree in Chemistry and completed his PhD at Imperial College, London. He was awarded a NATO Postdoctoral Research Fellowship and spent two years at Columbia University, New York, working in molecular recognition.


We are ViiV Healthcare: 100% dedicated to HIV medicines and research and focused on people living with HIV and AIDS.

Together we are engaged in the HIV response throughout the world, supported by a team of over 1,100 dedicated ViiV Healthcare staff working across the globe.

Discover more about who we are, the work we do and what we're doing to advance HIV science, support the delivery of HIV treatment and care; and work with partners to address the stigma and discrimination faced by people living with HIV.